Functional Characterization of Thrombospondin-2 in Bone Extracellular Matrix

骨细胞外基质中 Thrombospondin-2 的功能表征

基本信息

  • 批准号:
    8895837
  • 负责人:
  • 金额:
    $ 11.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-18 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of the 5 year career development plan outlined in this KO1 application is to foster the development of the candidate, Dr. Alford into a productive, independent investigator in the field of osteoblast cellular and extracellular matrix biology. Under the guidance of her mentors, Drs Steven A Goldstein and Renny T Franceschi, and through regular interactions with expert consultants, Stephen J. Weiss and Kurt D. Hankenson, the candidate will carry out the proposed research as a member of the Orthopaedic Research Laboratories in the Department of Orthopaedic Surgery at the University of Michigan. In the 5 year research plan proposed here, we will utilize primary MSC harvested from TSP2-null mice and their littermates in a well established in vitro model of osteoblastogenesis to test the global hypothesis that matrix-bound TSP2 makes specific contributions to osteoblast lineage progression which are dependent on the differentiation state of the cell, as well as on the unique extracellular milieu associated with matrix assembly, maturation and mineralization. Specifically, in aim 1 we will address the working hypothesis that in the context of early osteoblast-differentiation events, TSP2 promotes the assembly of a type I collagen-rich osteoblast-derived extracellular matrix, and as a result, it indirectly promotes collagen-dependent signal transduction events that are critical for osteoblast differentiation. In specific aim 2, we will address the premise that, in the context of matrix mineralization, TSP2 makes an additional unique contribution to osteoblast maturation. Specifically, we hypothesize that TSP2 is proteolytically processed to release biologically relevant fragments that affect matrix mineralization. Together, the experiments outlined in this proposal will define differentiation-stage dependent contributions that TSP2 makes to osteoblast lineage progression and matrix mineralization.
描述(由申请人提供):这份KO1申请表中概述的5年职业发展计划的目标是将候选人Alford博士培养成成骨细胞和细胞外基质生物学领域的一名富有成效的独立研究员。在她的导师Steven A Goldstein和Renny T Franceschi博士的指导下,通过与专家顾问Stephen J.Weiss和Kurt D.Hankenson的定期互动,候选人将作为密歇根大学整形外科系整形外科研究实验室的成员开展拟议中的研究。在这里提出的5年研究计划中,我们将利用从TSP2基因缺失的小鼠及其子代获得的原代MSC,在成熟的成骨细胞体外模型中,测试基质结合的TSP2对成骨细胞系进程的特定贡献这一全球假说,这取决于细胞的分化状态,以及与基质组装、成熟和矿化相关的独特的细胞外环境。具体地说,在目标1中,我们将解决工作假说,即在早期成骨细胞分化事件的背景下,TSP2促进富含I型胶原的成骨细胞来源的细胞外基质的组装,从而间接促进对成骨细胞分化至关重要的胶原依赖的信号转导事件。在特定的目标2中,我们将解决的前提是,在基质矿化的背景下,TSP2对成骨细胞的成熟做出了额外的独特贡献。具体地说,我们假设TSP2被蛋白质降解处理以释放影响基质矿化的生物相关片段。总之,这项提案中概述的实验将确定TSP2对成骨细胞谱系进展和基质矿化的依赖于分化阶段的贡献。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Thrombospondin-2 facilitates assembly of a type-I collagen-rich matrix in marrow stromal cells undergoing osteoblastic differentiation.
  • DOI:
    10.3109/03008207.2013.811236
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Alford AI;Golicz AZ;Cathey AL;Reddy AB
  • 通讯作者:
    Reddy AB
Two molecular weight species of thrombospondin-2 are present in bone and differentially modulated in fractured and nonfractured tibiae in a murine model of bone healing.
  • DOI:
    10.1007/s00223-012-9580-y
  • 发表时间:
    2012-05
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Alford, Andrea I.;Reddy, Anita B.;Goldstein, Steven A.;Murthy, Prithvi;Tayim, Riyad;Sharma, Gorav
  • 通讯作者:
    Sharma, Gorav
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREA I ALFORD其他文献

ANDREA I ALFORD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREA I ALFORD', 18)}}的其他基金

Targeting Pathological Angiogenesis after Joint Injury
针对关节损伤后的病理性血管生成
  • 批准号:
    10214725
  • 财政年份:
    2021
  • 资助金额:
    $ 11.23万
  • 项目类别:
Functional Characterization of Thrombospondin-2 in Bone Extracellular Matrix
骨细胞外基质中 Thrombospondin-2 的功能表征
  • 批准号:
    8189335
  • 财政年份:
    2011
  • 资助金额:
    $ 11.23万
  • 项目类别:
Functional Characterization of Thrombospondin-2 in Bone Extracellular Matrix
骨细胞外基质中 Thrombospondin-2 的功能表征
  • 批准号:
    8709809
  • 财政年份:
    2011
  • 资助金额:
    $ 11.23万
  • 项目类别:
Functional Characterization of Thrombospondin-2 in Bone Extracellular Matrix
骨细胞外基质中 Thrombospondin-2 的功能表征
  • 批准号:
    8513773
  • 财政年份:
    2011
  • 资助金额:
    $ 11.23万
  • 项目类别:
Functional Characterization of Thrombospondin-2 in Bone Extracellular Matrix
骨细胞外基质中 Thrombospondin-2 的功能表征
  • 批准号:
    8322051
  • 财政年份:
    2011
  • 资助金额:
    $ 11.23万
  • 项目类别:
A Pre-Clinical Surgical Model of the Induced-Membrane Technique for the Management of Segmental Bone Defects
用于治疗节段性骨缺损的诱导膜技术的临床前手术模型
  • 批准号:
    9540254
  • 财政年份:
  • 资助金额:
    $ 11.23万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 11.23万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 11.23万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了